

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Continuation of 09/661,836
Sheet	1	of	4	Filing Date	December 4, 2001
				First Named Inventor	James Ronald Lawter
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ORA 100/102 CON

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
HW	3,966,808	Luciano		06-29-1976		
	4,961,926	Gabrilove		10-09-1990		
	5,082,653	Pan et al.		01-21-1992		
	5,102,870	Florine et al.		04-07-1992		
	5,284,963	Sum et al.		02-08-1994		
	5,328,902	Sum et al.		07-12-1994		
	5,386,041	Sum et al.		01-31-1995		
	5,401,729	Sum et al.		03-28-1995		
	5,420,272	Sum et al.		05-30-1995		
	5,430,162	Sum et al.		07-04-1995		
	5,545,668	Skubitz et al.		08-13-1996		
	5,635,489	Haley		06-03-1997		
	5,827,840	Ramanurthy et al.		10-27-1998		
	5,886,175	Sum et al.		03-23-1999		
	5,945,089	Lubin		08-31-1999		
HW	5,981,499	Hau		11-09-1999		
	6,025,326	Steinberg et al.		02-15-2000		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
HW	WO 94/27579	A1		Ribogene, Inc.	12-08-1994	
EW	WO 98/18610	A1		Bernard Van Lengerich	05-07-1998	
EW	WO 99/22703	A1		Lurident Ltd.	05-14-1999	
HW	WO 99/45910	A2		Mucosal Therapeutics LLC	09-16-1999	
EW	WO 00/07601	A1		Advanced Vision Research	02-17-2000	

Examiner Signature	<i>Welman</i>	Scc	Date Considered	1/25/02, 2/05
--------------------	---------------	-----	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	Continuation of 09/661,836
Sheet	2	of	4
		Attorney Docket Number	ORA 100/102 CON

12/04/01

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
<i>ewj</i>	BARKER, et al., "Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis," <i>J Pediatr Hematol Oncol</i> 17(2):151-55 (1995).	
<i>✓</i>	CARTEE, et al., "Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study," <i>Cytokine</i> 7(5):471-7 (1994).	
<i>✓</i>	CHI, et al., "Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy," <i>J Clin Oncol.</i> 13(10):2620-28 (1995).	
	CUTLER & SCHUBERT, "Patient factors affecting <i>Helicobacter pylori</i> eradication with triple therapy," <i>American Journal of Gastroenterology</i> 88(4):505-509 (1993).	
<i>✓</i>	EPSTEIN & WONG, "The efficacy of sucralfate suspension in the prevention of oral mucositis due to radiation therapy," <i>Int. J. Radiat. Oncol. Biol. Phys.</i> 28(3):693-98 (1994).	
<i>✓</i>	EPSTEIN, et al., "Benzydamine hydrochloride in prevention and management of pain in oral mucositis associated with radiation therapy," <i>Oral Surg. Oral Med. Oral Pathol.</i> 62(2):145-8 (1986).	
<i>✓</i>	EPSTEIN, et al., "Prevention of oral mucositis in radiation therapy: a controlled study with benzydamine hydrochloride rinse," <i>Int. J. Radiation Oncology Biol. Phys.</i> 16(6):1571-5 (1989).	
<i>✓</i>	<i>Essentials of Medicinal Chemistry</i> John Wiley and Sons, Inc., pp 512-517 (1976).	
	FACCHINI, et al., "Attività di flunoxaprofene per uso topico nelle vaginiti aspecifiche. Confronto con mecloclicina solfosalicilato," <i>Minerva Ginecologica</i> 41(12):609-614 (1989).	
<i>✓</i>	FERRETTI, et al., "Control of oral mucositis and candidiasis in marrow transplantation: a prospective, double-blind trial of chlorhexidine digluconate oral rinse," <i>Bone Marrow Transplant</i> 3(5):483-93 (1990).	

Examiner's Signature	<i>Dekayne Ew</i>	Date Considered	<i>1/25/02 2/05</i>
----------------------	-------------------	-----------------	---------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document; by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-98)
Approved for use through 10/31/99. OMB 0551-0031
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Continuation of 09/661,836
Sheet:	3	of	4	Filing Date	December 4, 2001
				First Named Inventor	James Ronald Lawter
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	ORA 100/102 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			
EW	✓	FOOTE, et al., "Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis," <i>J. Clin Oncol.</i> 12(12):2630-33 (1994).			T-2
		FRANCESCHI, et al., "Solitary J-pouch ulcer causing pouchitis-like syndrome," <i>Diseases of the Colon and Rectum</i> 29(8):515-517 (1986).			
	✓	LOPRINZI, et al., "Alleviation of cytotoxic therapy-induced normal tissue damage," <i>Sem. Oncol.</i> 22(2) Suppl. 3:95-97 (1995).			
	✓	MITSCHER, et al., "Quinolone antimicrobial agents. 1. Versatile new synthesis of 1-alkyl-1,4-dihydro-4-oxo-3-quinolincarboxylic acids," <i>J. Med. Chem.</i> 21(5):485-9 (1978).			
		ROTHWELL & SPEKTOR, "Palliation of radiation-related mucositis," <i>Special Care in Dentistry</i> 10(1):21-25 (1990).			
		SCHENK, et al., "Controlled local delivery of tetracycline HCl in the treatment of periimplant mucosal hyperplasia and mucositis," <i>Clinical Oral Implants Research</i> 8(5):427-433 (1997).			
	✓	SONIS, 1993b, "Oral Complications in Cancer Therapy," In: <i>Principles and Practice of Oncology</i> , De Vita et al., eds., pp. 2385-2394 (J. B. Lippincott, Philadelphia).			
	J	<i>Special Care in Dentistry</i> Jan.-Feb, pages 21-25 (1990).			
	J	SPIJKERVELT, et al., "Chlorhexidine inactivation by saliva," <i>Oral Surg. Oral Med. Oral Pathol.</i> 69(4):444-49 (1990).			
EW	J	VERDI, et al., "A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis," <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.</i> 80(1):36-42 (1995).			

Examiner's Signature	<i>Weller Jr., EW</i>	Date Considered	1/25/02, 2/05
----------------------	-----------------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
				Application Number	Continuation of 09/661,836
				Filing Date	December 4, 2001
				First Named Inventor	James Ronald Lawter
				Group Art Unit	
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	ORA 100/102 CON

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>flm</i>	v.	WEISDORF, et al., "Oropharyngeal mucositis complicating bone marrow transplantation: prognostic factors and the effect of chlorhexidine mouth rinse," <i>Bone Marrow Transplant</i> 4(1):89-95 (1989).	

Examiner's Signature	<u>Welen Jr.</u>	Date- Considered	1/25/02
-------------------------	------------------	---------------------	---------

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the issue of the Examiner must precede the serial number of the patent document.

Standard ST.3. For Japanese patent documents, the indication of the year or the reign of the Emperor must precede the serial number of the patent document.
* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant to place a check mark here if English language Translation is attached.

Please Note: This form is estimated to take 2-3 hours to complete. Time will vary depending upon the needs of the individual case. Any comments

on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.